Rolipram (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rolipram" in Serbian language version.

refsWebsite

Global rank Serbian rank

10nih.gov

4^th place

8^th place

10doi.org

2^nd place

4^th place

1pnas.org

1,293^rd place

802^nd place

1web.archive.org

1^st place

1dtic.mil

833^rd place

2,353^rd place

1jstor.org

26^th place

57^th place

doi.org (Global: 2^nd place; Serbian: 4^th place)

Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ (1993). „Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response”. Inflammation. 17 (3): 333—44. PMID 7687237. doi:10.1007/BF00918994.
Wachtel H. (1983). „Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors”. Neuropharmacology. 22 (3): 267—72. PMID 6302550. doi:10.1016/0028-3908(83)90239-3.
Maxwell CR, Kanes SJ, Abel T, Siegel SJ (2004). „Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications”. Neuroscience. 129 (1): 101—7. PMID 15489033. doi:10.1016/j.neuroscience.2004.07.038.
Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP (2006). „Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity”. Neuroscience. 144 (1): 239—46. PMID 17081698. doi:10.1016/j.neuroscience.2006.09.026.
Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998). „Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory”. Proceedings of the National Academy of Science of the USA. 95 (25): 15020—5. PMC 24568 . PMID 9844008. doi:10.1073/pnas.95.25.15020.
Lelkes Z, Alföldi P, Erdos A, Benedek G (1998). „Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats”. Pharmacology, Biochemistry and Behaviour. 60 (4): 835—9. PMID 9700966. doi:10.1016/S0091-3057(98)00038-0.
Block F, Schmidt W, Nolden-Koch M, Schwarz M (2001). „Rolipram reduces excitotoxic neuronal damage”. Neuroreport. 12 (7): 1507—11. PMID 11388438. doi:10.1097/00001756-200105250-00041.
Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC, Dave JR (2007). „Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation”. Neuroscience Letters. 418 (2): 165—9. PMID 17398001. doi:10.1016/j.neulet.2007.03.033.
Smith, Donna L; J, Pozueta; et al. (14. 9. 2009). „Reversal of long-term dendritic spine alterations in Alzheimer disease models”. Proceedings of the National Academy of Sciences of the United States. 106 (39): 16877—16882. PMC 2743726 . PMID 19805389. doi:10.1073/pnas.0908706106. Приступљено 13. 11. 2009.
Nikulina, E. (8. 6. 2004). „The Phosphodiesterase Inhibitor Rolipram Delivered after a Spinal Cord Lesion Promotes Axonal Regeneration and Functional Recovery”. Proceedings of the National Academy of Sciences of the United States. 101: 8786. JSTOR 3372336. doi:10.1073/pnas.0402595101.

dtic.mil (Global: 833^rd place; Serbian: 2,353^rd place)

handle.dtic.mil

MF, Beal; C, Cleren; et al. (2005). „Oxidative Damage in Parkinson's Disease”. U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012. Архивирано из оригинала 23. 05. 2012. г. Приступљено 13. 11. 2009.

jstor.org (Global: 26^th place; Serbian: 57^th place)

Nikulina, E. (8. 6. 2004). „The Phosphodiesterase Inhibitor Rolipram Delivered after a Spinal Cord Lesion Promotes Axonal Regeneration and Functional Recovery”. Proceedings of the National Academy of Sciences of the United States. 101: 8786. JSTOR 3372336. doi:10.1073/pnas.0402595101.

nih.gov (Global: 4^th place; Serbian: 8^th place)

ncbi.nlm.nih.gov

Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ (1993). „Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response”. Inflammation. 17 (3): 333—44. PMID 7687237. doi:10.1007/BF00918994.
Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H (1988). „Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives”. Eur Arch Psychiatry Neurol Sci. 238 (1): 2—6. PMID 3063534.
Wachtel H. (1983). „Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors”. Neuropharmacology. 22 (3): 267—72. PMID 6302550. doi:10.1016/0028-3908(83)90239-3.
Maxwell CR, Kanes SJ, Abel T, Siegel SJ (2004). „Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications”. Neuroscience. 129 (1): 101—7. PMID 15489033. doi:10.1016/j.neuroscience.2004.07.038.
Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP (2006). „Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity”. Neuroscience. 144 (1): 239—46. PMID 17081698. doi:10.1016/j.neuroscience.2006.09.026.
Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998). „Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory”. Proceedings of the National Academy of Science of the USA. 95 (25): 15020—5. PMC 24568 . PMID 9844008. doi:10.1073/pnas.95.25.15020.
Lelkes Z, Alföldi P, Erdos A, Benedek G (1998). „Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats”. Pharmacology, Biochemistry and Behaviour. 60 (4): 835—9. PMID 9700966. doi:10.1016/S0091-3057(98)00038-0.
Block F, Schmidt W, Nolden-Koch M, Schwarz M (2001). „Rolipram reduces excitotoxic neuronal damage”. Neuroreport. 12 (7): 1507—11. PMID 11388438. doi:10.1097/00001756-200105250-00041.
Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC, Dave JR (2007). „Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation”. Neuroscience Letters. 418 (2): 165—9. PMID 17398001. doi:10.1016/j.neulet.2007.03.033.
Smith, Donna L; J, Pozueta; et al. (14. 9. 2009). „Reversal of long-term dendritic spine alterations in Alzheimer disease models”. Proceedings of the National Academy of Sciences of the United States. 106 (39): 16877—16882. PMC 2743726 . PMID 19805389. doi:10.1073/pnas.0908706106. Приступљено 13. 11. 2009.

pnas.org (Global: 1,293^rd place; Serbian: 802^nd place)

Smith, Donna L; J, Pozueta; et al. (14. 9. 2009). „Reversal of long-term dendritic spine alterations in Alzheimer disease models”. Proceedings of the National Academy of Sciences of the United States. 106 (39): 16877—16882. PMC 2743726 . PMID 19805389. doi:10.1073/pnas.0908706106. Приступљено 13. 11. 2009.

web.archive.org (Global: 1^st place; Serbian: 1^st place)

MF, Beal; C, Cleren; et al. (2005). „Oxidative Damage in Parkinson's Disease”. U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012. Архивирано из оригинала 23. 05. 2012. г. Приступљено 13. 11. 2009.

Rolipram (Serbian Wikipedia)

doi.org (Global: 2nd place; Serbian: 4th place)

dtic.mil (Global: 833rd place; Serbian: 2,353rd place)

handle.dtic.mil

jstor.org (Global: 26th place; Serbian: 57th place)

nih.gov (Global: 4th place; Serbian: 8th place)